Evaluation of IL-33 in Patients With the Acute Ischemic Stroke
Evaluation of IL-33 in Patients With the Acute Ischemic Stroke
Aim of the study is to evaluate the usefulness of interleukin 33 in the blood plasma in
 patients with the acute ischemic stroke of the brain in relation to mode of treatment
 (thrombolysis, thrombectomy, no treatment), risk factors in correlation with other
 inflammatory state markers (hsCRP, morphology with smear ). Blood is collected on the first
 and seventh days of stroke.

 The purpose is to clarify utility of IL 33 as a biomarker of acute stroke.
Stroke is the third most frequent cause of death in highly developed countries (after heart
 disease and cancer), the main cause of disability in adults and the second most frequent
 cause of dementia syndromes. The annual incidence of stroke in the general population is
 approximately 0.2%. The risk of stroke increases with age.

 Globally 15 million people are affected each year and 5.5 million die every year for this
 reason (20% in 30 days and up to 40% in a year from getting ill). In Poland, the incidence of
 stroke is around 175/100,000 in men and 125/100 in women.It is assumed that the cause of
 sudden cerebral insufficiency is mainly the embolism coming from the newly formed wall clot
 forming at the site of the atherosclerotic plaque rupture.

 In recent years, the role of inflammatory factors is associated with the occurrence of severe
 atherosclerotic complications such as stroke or heart attack. Cytokines are glycoproteins
 that are released by activated cells of various tissues. They have a significant impact on
 the inflammation processes, they control all phases of the immune response. Interleukin is
 one of the cytokine groups. This study aims to find a relationship between level of IL 33
 concentration and the size of the stroke and neurological deficit.

 Blood will be collected on the first and seventh days of stroke for examination of Il 33,
 blood morphology and hsCRP
Inclusion Criteria:

 -  Age over 18

 -  Consent on participation

 -  Diagnosed Ischemic Stroke

 Exclusion Criteria:

 -  Active cancer disease

 -  Kidney failure

 -  Liver failure

 -  Pregnancy

 -  Breastfeeding